Most Popular Stories
- Case study: NYC works to manage diabetes
- Verizon is the latest telecom to seek riches in mobile healthcare
- 20 percent of diabetics are 100 pounds overweight, study concludes
- Alabama MDs say state Blue plan hasn't followed class-action agreement
- Study: Number of HIEs going online up about 40 percent since 2008
- DTC pharma ads could raise Medicaid costs
Featured Jobs
-
Physical Therapist
Makro Health - Erie, PA -
Med/Surg Oncology RN Job in New York
StaffPointe, LLC - near Plattsburgh, NY -
Physician Assistant Job in Texas
StaffPointe, LLC - near Dallas, TX -
RN Mgr Adult/Geri Psych Prog Job in MI
StaffPointe, LLC - south central, MI -
Family Practice Job in Indiana
StaffPointe, LLC - near Lawrenceburg, IN
Events
- Security Audits: Is Your Organization Prepared and In Compliance?
Dec.3 at 12 pm CT - Harvard Business School 7th Healthcare Conference
January 30, 2010
Paid Research Reports
- Pricing and Reimbursement in Key Asia Pacific Markets
- Delivery Mechanisms for Large Molecule Drugs: Successes and failures of leading technologies and key drivers for market success
- The Cardiovascular Market Outlook to 2013: Competitive landscape, global market analysis and pipeline analysis
- Intellectual Property and Outsourcing in China: Minimizing risk whilst maximizing return on investment
- Health Care Equipment & Supplies: Global Industry Guide
- 2009 Trends to Watch: Healthcare Technology
FEATURES >> YouTube | Top acute-care hospitals | Women in Health IT | Top BlackBerry Apps | Commentary
TOPICS >> Stimulus | Health Reform | CMS News | Finance | EMRs | Mobile Healthcare | Hospital Leadership Blog
Free Newsletter
FierceHealthcare is the leading source of healthcare management news for healthcare industry executives. Join 50,000+ healthcare industry insiders who get FierceHealthcare via daily email. Sign up today!
Popular Topics
- Medicare
- health plans
- Centers for Medicare and Medicaid Services (CMS)
- Insurance
- Electronic Medical Records (EMRs)
- Food and Drug Administration (FDA)
- Department of Health and Human Services (HHS)
- Medicaid
- American Medical Association (AMA)
- healthcare system
- health reform
- prescription drugs
- pharmaceutical companies
FDA, drug makers to study drug side-effects
A group of the world's biggest drug makers have come together with the FDA to look into the reasons why a small subset of patients have medication severe side effects. To attack the problem, the International Severe Adverse Events Consortium hopes to use personalized medicine. The partners will be working to use genetic data to design less-dangerous drugs, as well as to find patients at risk for serious side effects.
Not only will the coalition bring the FDA under the same mantle as drug companies, it will also lead to a major lowering of competitive barriers. The drug companies involved, including Abbott, GlaxoSmithKline, Johnson & Johns and Roche, will share data with researchers across the world using a mutual database. The FDA's role, meanwhile, will be to offer advice on how to design the research and make sense of the results. Other partners include Columbia University and two European academic consortia.
To find out more about the coalition:
- read this piece in The Boston Globe
Related Articles:
Can we afford personalized medicine? Report
Personalized medicine initiative hopes for grant. Report
Congress poised to give more power to the FDA. Report
Researcher challenges FDA approval process. Report
Bill giving FDA more drug safety powers could pass. Report
FDA emphasizing speed over safety? Report
FDA boosts reviews for new drugs. Report
Report faults FDA's post-marketing vigilance. Report
Related Stories
- Avandia slammed by more studies
- Did Glaxo conceal Paxil users' risk of suicide?
- ALSO NOTED: U of Miami suffers massive patient data loss; Loyola U sets $1B strategic plan; and much more...
- FDA says Glaxo didn't report Avandia data
- In wake of Avandia scandal, drugmaker pitches Actos as safe
- Avandia gets black-box warning
- FDA panel votes to keep Avandia on the market
- Glaxo: Avandia critic should pay for stock drop
- Glaxo: Avandia's safe as other diabetes drugs
- Press Release: FDA Approves Alli(TM) (orlistat 60 Mg Capsules) Over-The-Counter
Comments
Post new comment
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site Map | List in Marketplace | Supplier MarketplaceTHE FIERCEMARKETS NETWORKFierceFinance | FierceFinanceIT | FierceComplianceIT | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceMobileHealthcare | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceGovernmentIT | FierceBiotech | FierceBiotech Research | FiercePharma | FierceVaccines | FierceBiotechIT | FiercePharma Manufacturing | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceVoIP | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe© 2009 FierceMarkets, Inc. All rights reserved. |
![]() |





